News

Video

The Utility of CAR T-Cell Therapy in Myelofibrosis

Author(s):

Fact checked by:

Dr. Matthew Ku discusses what CAR T-cell therapy is and how it works to target diseases like myelofibrosis.

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr. Matthew Ku, who went on to add that this is an unmet need.

This unmet need is then combatted by researchers who have developed a method to genetically engineer T cells to express receptors that specifically target tumor cells, allowing the modified T cells to recognize and attack cancer more effectively. Ongoing research such as the 'Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)' is studying how clinical and genetic patterns in low-risk myelofibrosis could inform disease progression and identify patients who may benefit from future targeted therapies.

Ku, a clinical and laboratory hematologist, is a professor and lymphoma stream lead at St Vincent’s Hospital, where he is also the principal investigator on multiple important clinical trials. He is a member of the Australasian Lymphoma Alliance, the Australasian Leukemia & Lymphoma Group and the American Society of Hematology.

Transcript:

Can you explain what CAR T-cell therapy is and how it works to target disease?

We all have T cells in our blood. These T cells are part of our natural, native immune system; they are meant to protect us against infections and cancers. However, when a patient has a cancer like lymphoma, it means the T cells have not properly done their job of eliminating that malignancy. This new method is a way of weaponizing T cells.

The process involves genetically modifying these T cells to express receptors that specifically target tumor cells. This can be done in two ways: autologous, where T cells are harvested from the patient's own blood or body, or allogeneic, where T cells come from another person, a healthy donor. A new DNA construct is introduced into these T cells using a viral method. This construct basically goes inside the T cells and makes them produce receptors that target the tumor cells.

The receptors will differ depending on the type of tumor cells being targeted. For example, if it's a B-cell tumor, the targets could be CD19 or CD20, but other types of receptors have also been created for other cancers. These modified cells are then reintroduced back into the patient, and ideally, they will persist, grow, and attack the tumor cells.

Transcript has been edited for clarity and conciseness

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of valarie with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content